This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Bio-Rad
other brands :
Biogenesis, Serotec, AbD Serotec, Oxford Biotechnology
product type :
antibody
product name :
Human anti Human INHIBIN ALPHA
catalog :
HCA070
quantity :
0.1 mg
price :
217 USD
clonality :
monoclonal
host :
human
conjugate :
nonconjugated
clone name :
AbD05070
reactivity :
human, mouse
application :
immunohistochemistry - paraffin section
citations: 1
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry - paraffin section; mouse; 1:200
Cai K, Wang Y, Smith E, Smedberg J, Yang D, Yang W, et al. Global deletion of Trp53 reverts ovarian tumor phenotype of the germ cell-deficient white spotting variant (Wv) mice. Neoplasia. 2015;17:89-100 pubmed publisher
product information
EntityType :
Monoclonal Antibody
EntityCategory :
Antibodies
ProductCode :
HCA070
Description :
HUMAN ANTI HUMAN INHIBIN ALPHA
Specificity :
INHIBIN ALPHA
TargetSpecies :
Human
Host :
Human
Format :
Purified
Isotypes :
HuCAL Fab bivalent
Applications :
C, E, P*
ApplicationTypes :
Immunohistology - Frozen, Immunohistology - Paraffin, ELISA
Clone :
AbD05070
Quantity :
0.1 mg
QuantityValue :
0.1
QuantityType :
mg
GOAccessions :
GO:0001501, GO:0001541, GO:0004871, GO:0005125, GO:0005179, GO:0006917, GO:0007050, GO:0007166, GO:0007267, GO:0007399, GO:0008083, GO:0009605, GO:0046881, GO:0046882, GO:0030218, GO:0034673, GO:0042127, GO:0042326, GO:0042541, GO:0043512, GO:0045077, GO:0045578, GO:0045650
GOTerms :
activation of apoptosis, activation of follicle-stimulating hormone secretion, apoptosis activator activity, apoptosis signaling, arrest of cell cycle progression, autocrine activity, cAMP generating peptide activity, cell surface receptor linked signal transduction, cell surface receptor linked signalling pathway, cell-cell signalling, cessation of cell cycle, commitment to apoptosis, down regulation of B cell differentiation, down regulation of follicle-stimulating hormone secretion, down regulation of interferon-gamma biosynthetic process, down regulation of macrophage differentiation, down regulation of phosphorylation, downregulation of B cell differentiation, down-regulation of B cell differentiation, down-regulation of follicle-stimulating hormone secretion, downregulation of follicle-stimulating hormone secretion, down-regulation of interferon-gamma biosynthetic process, downregulation of interferon-gamma biosynthetic process, downregulation of macrophage differentiation, down-regulation of macrophage differentiation, downregulation of phosphorylation, down-regulation of phosphorylation, erythrocyte cell differentiation, erythropoiesis, follicular phase, glycopeptide hormone, GO:0005062, GO:0009369, GO:0009370, gp130, haemoglobin biosynthesis, haemoglobin biosynthetic process, hematopoietin/interferon-class (D200-domain) cytokine receptor signal transducer activity, hemoglobin anabolism, hemoglobin biosynthesis, hemoglobin formation, hemoglobin synthesis, induction of apoptosis by p53, inhibition of B cell differentiation, inhibition of follicle-stimulating hormone secretion, inhibition of interferon-gamma biosynthetic process, inhibition of macrophage differentiation, inhibition of phosphorylation, lipopeptide hormone, negative regulation of B cell development, negative regulation of B lymphocyte differentiation, negative regulation of B-cell differentiation, negative regulation of B-lymphocyte differentiation, negative regulation of follicle stimulating hormone secretion, negative regulation of interferon-gamma anabolism, negative regulation of interferon-gamma biosynthesis, negative regulation of interferon-gamma formation, negative regulation of interferon-gamma synthesis, pan-neural process, paracrine activity, peptide hormone, positive regulation of follicle stimulating hormone secretion, quorum sensing response regulator activity, quorum sensing signal generator activity, RBC differentiation, red blood cell differentiation, response to environmental stimulus, skeletal development, stimulation of follicle-stimulating hormone secretion, termination of cell cycle, up regulation of follicle-stimulating hormone secretion, up-regulation of follicle-stimulating hormone secretion, upregulation of follicle-stimulating hormone secretion
UniprotAccessions :
P05111
Gene :
INHA
GeneID URL :
www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3623
EntityFormats :
Purified
UNSPSC :
12352203
Concentration :
Antibody concentration 0.5 mg/ml
ProductForm :
A bivalent human recombinant Fab (kappa light chain) selected from the HuCAL® GOLD phage display library. Expressed in E. coli and purified using metal chelate affinity chromatography. This Fab fragment is dimerized via a helix-turn-helix motif. The antibody is tagged with a myc-tag (EQKLISEEDL) and a his-tag (HHHHHH) at the C-terminus of the antibody heavy chain.
PriceDKK :
1615
PrimarySecondary :
Primary
PriceGBP :
155
PriceEUR :
217
PriceUSD :
217 USD
PriceCHF :
254
PriceSEK :
2163
PriceNOK :
2149
company information
Bio-Rad
Endeavour House, Langford Business Park
Langford Lane, Kidlington
OXON, OX5 1GE
antibody_sales_uk@bio-rad.com
https://www.bio-rad-antibodies.com
1 800 265 7376 (North America)
44 (0)1865 852 700 (Rest of World)
headquarters: UK
Bio-Rad is one of the world's leading antibody manufacturers, offering over 12,000 antibodies and related reagents for a focused range of research areas such as immunology, cancer, veterinary research and cell biology through its antibody experts formerly known as AbD Serotec.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.